Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY - Get Free Report) traded up 1.6% on Monday . The stock traded as high as $23.66 and last traded at $23.57. 243,417 shares were traded during trading, a decline of 34% from the average session volume of 368,726 shares. The stock had previously closed at $23.19.
Chugai Pharmaceutical Stock Performance
The stock has a market cap of $81.32 billion, a PE ratio of 31.28 and a beta of 0.66. The stock has a fifty day moving average price of $25.17 and a 200 day moving average price of $24.48.
Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last issued its quarterly earnings results on Thursday, July 24th. The company reported $0.20 earnings per share (EPS) for the quarter. The firm had revenue of $2.01 billion during the quarter. Chugai Pharmaceutical had a return on equity of 21.35% and a net margin of 33.08%. As a group, equities analysts anticipate that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current fiscal year.
About Chugai Pharmaceutical
(
Get Free Report)
Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.
Recommended Stories
Before you consider Chugai Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chugai Pharmaceutical wasn't on the list.
While Chugai Pharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access